Cite
HARVARD Citation
Phillips, I. et al. (2022). In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy – No' by Macbeth and Hughes-Davies. Clinical oncology. 34 (4), pp. e169-e170. [Online].